- Home
- IMMP vs LUNG Comparison
IMMP vs LUNG Comparison
Compare IMMP & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- LUNG
- Stock Information
- Founded
- IMMP 1987
- LUNG 1995
- Country
- IMMP Australia
- LUNG United States
- Employees
- IMMP N/A
- LUNG N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- LUNG Industrial Specialties
- Sector
- IMMP Health Care
- LUNG Health Care
- Exchange
- IMMP Nasdaq
- LUNG Nasdaq
- Market Cap
- IMMP 264.7M
- LUNG 290.8M
- IPO Year
- IMMP N/A
- LUNG 2020
- Fundamental
- Price
- IMMP $2.05
- LUNG $6.34
- Analyst Decision
- IMMP Buy
- LUNG Strong Buy
- Analyst Count
- IMMP 2
- LUNG 6
- Target Price
- IMMP $8.50
- LUNG $13.83
- AVG Volume (30 Days)
- IMMP 106.2K
- LUNG 233.5K
- Earning Date
- IMMP 11-26-2024
- LUNG 10-30-2024
- Dividend Yield
- IMMP N/A
- LUNG N/A
- EPS Growth
- IMMP N/A
- LUNG N/A
- EPS
- IMMP N/A
- LUNG N/A
- Revenue
- IMMP $2,563,302.00
- LUNG $79,302,000.00
- Revenue This Year
- IMMP N/A
- LUNG $22.26
- Revenue Next Year
- IMMP $10.84
- LUNG $18.72
- P/E Ratio
- IMMP N/A
- LUNG N/A
- Revenue Growth
- IMMP 9.59
- LUNG 22.34
- 52 Week Low
- IMMP $1.58
- LUNG $5.46
- 52 Week High
- IMMP $3.34
- LUNG $14.84
- Technical
- Relative Strength Index (RSI)
- IMMP 55.82
- LUNG 41.84
- Support Level
- IMMP $1.85
- LUNG $7.21
- Resistance Level
- IMMP $2.06
- LUNG $7.67
- Average True Range (ATR)
- IMMP 0.10
- LUNG 0.54
- MACD
- IMMP 0.03
- LUNG -0.02
- Stochastic Oscillator
- IMMP 70.89
- LUNG 16.38
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.